Amsterdam, 27 May 2009 – Last week marked the celebration of International Clinical Trials' Day 2009. A worldwide coalition of health and human rights organizations united in the campaign FairDrugs.org called for the adequate protection of trial subjects in developing countries.
The campaign, led by the Wemos Foundation, centres on the Call for Ethical Clinical Trials in Developing Countries, and appeals to policymakers, legislators and pharmaceutical companies to respect the rights of trial subjects. Numerous organizations and individuals have already signed up, including independent investigative journalist Sonia Shah, the author of The Body Hunters: Testing New Drugs on the World's Poorest Patients. ‘For too long, clinical trials in poor countries have been conducted in the shadows, endangering the human rights and health of test subjects. I support the FairDrugs.org campaign because I believe civil society must be involved to ensure that all human experimentation is conducted to the highest ethical standards. Anyone who benefits from modern medications should, too’, says Sonia Shah.
Positive
The European Medicines Agency (EMEA) recently announced its intention to improve supervision of compliance with ethical guidelines in clinical trials conducted outside the European Union (EU). This is a positive development, according to Wemos' Annelies den Boer: 'We have been expressing our concern about the increasing number of medicines being tested on people in developing countries since 2006. We have called for thoroughgoing ethical evaluations before medicines are given EU market approval. EMEA now intends to actually do this.'
Practical
'We are especially interested in how EMEA will tackle the practical application of international ethical guidelines. We hope that the latest version of the Declaration of Helsinki will be used as the starting point and that EMEA will consult experts in developing countries for advice.' Den Boer points out that the registration authorities in EU member states will also need to take action. 'Political support is essential, both at European level and within member states, if the steps proposed by EMEA are to be implemented. We see our role as one of mobilizing support and creating momentum, for example by means of FairDrugs.org.'
Letters
On International Clinical Trials' Day 2009, coalition members wrote letters to public health ministers across Europe, calling for measures to prevent further abuses of trial subjects in developing countries. Sandhya Srinivasan, editor of the Indian Journal of Medical Ethics, visited Amsterdam to discuss the risks of carrying out clinical trials in developing countries. She joined Wemos and the Centre for Research on Multinational Corporations (SOMO) in considering ways in which the position of vulnerable test subjects can be improved.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.